Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Bamlanivimab/etesevimab  COVID-19 treatment studies for Bamlaniv../e..  C19 studies: Bamlaniv../e..  Bamlaniv../e..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 95% Improvement Relative Risk Death/hospitalization 70% primary Recovery time 11% Viral clearance 67% Dougan et al. NCT04427501 Bamlanivimab/e.. RCT EARLY Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19? Double-blind RCT 1,035 patients in the USA Lower mortality (p=0.0019) and death/hosp. (p=0.00016) Dougan et al., New England J. Medicine, doi:10.1056/NEJMoa2102685 Favors bamlanivimab/e.. Favors control
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Dougan et al., New England Journal of Medicine, doi:10.1056/NEJMoa2102685, NCT04427501 (history)
Dougan et al., Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19, New England Journal of Medicine, doi:10.1056/NEJMoa2102685, NCT04427501
Oct 2021   Source   PDF  
  All Studies   Meta
Results from the BLAZE-1 RCT of combined bamlanivimab/etesevimab, showing significantly lower mortality and combined mortality/hospitalization with treatment. NCT04427501 (history).
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, VanBlargan].
risk of death, 94.7% lower, RR 0.05, p = 0.002, treatment 0 of 518 (0.0%), control 9 of 517 (1.7%), NNT 57, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), COVID-19 deaths.
risk of death/hospitalization, 69.5% lower, RR 0.30, p < 0.001, treatment 11 of 518 (2.1%), control 36 of 517 (7.0%), NNT 21, primary outcome.
recovery time, 11.1% lower, relative time 0.89, p = 0.007, treatment 518, control 517, sustained resolution of symptoms.
risk of no viral clearance, 66.6% lower, RR 0.33, p < 0.001, treatment 50 of 508 (9.8%), control 147 of 499 (29.5%), NNT 5.1, day 7, persistently high viral load.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Dougan et al., 7 Oct 2021, Double Blind Randomized Controlled Trial, USA, peer-reviewed, 33 authors, average treatment delay 4.0 days, trial NCT04427501 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBamlaniv../e..All
Abstract: T h e n e w e ng l a n d j o u r na l o f m e dic i n e Original Article Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 M. Dougan, A. Nirula, M. Azizad, B. Mocherla, R.L. Gottlieb, P. Chen, C. Hebert, R. Perry, J. Boscia, B. Heller, J. Morris, C. Crystal, A. Igbinadolor, G. Huhn, J. Cardona, I. Shawa, P. Kumar, A.C. Adams, J. Van Naarden, K.L. Custer, M. Durante, G. Oakley, A.E. Schade, T.R. Holzer, P.J. Ebert, R.E. Higgs, N.L. Kallewaard, J. Sabo, D.R. Patel, M.C. Dabora, P. Klekotka, L. Shen, and D.M. Skovronsky, for the BLAZE-1 Investigators*​​ A BS T R AC T BACKGROUND The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Skovronsky at Eli Lilly, 893 Delaware St., Indianapolis, IN 46225, or at ­skovronsky _daniel@​­lilly​.­com. *A list of the BLAZE-1 investigators is provided in the Supplementary Appendix, available at Drs. Dougan and Nirula contributed equally to this article. This article was published on July 14, 2021, at N Engl J Med 2021;385:1382-92. DOI: 10.1056/NEJMoa2102685 Copyright © 2021 Massachusetts Medical Society. CME at Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and may limit disease progression and complications. METHODS In this phase 3 trial, we randomly assigned, in a 1:1 ratio, a cohort of ambulatory patients with mild or moderate Covid-19 who were at high risk for progression to severe disease to receive a single intravenous infusion of either a neutralizing monoclonal-antibody combination agent (2800 mg of bamlanivimab and 2800 mg of etesevimab, administered together) or placebo within 3 days after a laboratory diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The primary outcome was the overall clinical status of the patients, defined as Covid-19–related hospitalization or death from any cause by day 29. RESULTS A total of 1035 patients underwent randomization and received an infusion of bamlanivimab–etesevimab or placebo. The mean (±SD) age of the patients was 53.8±16.8 years, and 52.0% were adolescent girls or women. By day 29, a total of 11 of 518 patients (2.1%) in the bamlanivimab–etesevimab group had a Covid-19– related hospitalization or death from any cause, as compared with 36 of 517 patients (7.0%) in the placebo group (absolute risk difference, −4.8 percentage points; 95% confidence interval [CI], −7.4 to −2.3; relative risk difference, 70%; P<0.001). No deaths occurred in the bamlanivimab–etesevimab group; in the placebo group, 10 deaths occurred, 9 of which were designated by the trial investigators as Covid-19–related. At day 7, a greater reduction from baseline in the log viral load was observed among patients who received bamlanivimab plus etesevimab than among those who received placebo (difference from placebo in the change from baseline, −1.20; 95% CI, −1.46 to −0.94; P<0.001). CONCLUSIONS Among high-risk ambulatory patients, bamlanivimab plus etesevimab led to a lower incidence of Covid-19–related hospitalization and death than did placebo and accelerated the decline in the SARS-CoV-2 viral load. (Funded by Eli Lilly; BLAZE-1 number, NCT04427501.) 1382 n engl j med 385;15 October 7, 2021 The New England Journal..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop